{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T11:53:23Z","timestamp":1723550003925},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1038\/s41417-020-0167-x","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:03:24Z","timestamp":1581033804000},"page":"898-909","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Non-toxic fragment of botulinum neurotoxin type A and monomethyl auristatin E conjugate for targeted therapy for neuroendocrine tumors"],"prefix":"10.1038","volume":"27","author":[{"given":"Jason","family":"Whitt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul R.","family":"Telange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chee Paul","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Bibb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Beebe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata","family":"Jaskula-Sztul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,7]]},"reference":[{"key":"167_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/erc.0.0110001","volume":"11","author":"MT Barakat","year":"2004","unstructured":"Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumours. Endocr Relat Cancer. 2004;11:1\u201318.","journal-title":"Endocr Relat Cancer"},{"key":"167_CR2","first-page":"587","volume":"13","author":"CQ Chen","year":"2010","unstructured":"Chen CQ, Chen HL, Cai SR, Wang Z, Ma JP, Zhang CH, et al. [Clinicopathologic features, diagnosis and treatment of 38 neuroendocrine carcinoma in the digestive system]. Zhonghua Wei Chang Wai Ke Za Zhi. 2010;13:587\u20139.","journal-title":"Zhonghua Wei Chang Wai Ke Za Zhi"},{"key":"167_CR3","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1634\/theoncologist.2008-0207","volume":"13","author":"SN Pinchot","year":"2008","unstructured":"Pinchot SN, Holen K, Sippel RS, Chen H. Carcinoid tumors. Oncologist. 2008;13:1255\u201369.","journal-title":"Oncologist."},{"key":"167_CR4","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000369818","volume":"100","author":"S Massironi","year":"2014","unstructured":"Massironi S, Rossi RE, Casazza G, Conte D, Ciafardini C, Galeazzi M, et al. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution. Neuroendocrinology. 2014;100:240\u20139.","journal-title":"Neuroendocrinology."},{"key":"167_CR5","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063\u201372.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"167_CR6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000080731","volume":"80","author":"BG Taal","year":"2004","unstructured":"Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology. 2004;80(Suppl 1):3\u20137.","journal-title":"Neuroendocrinology."},{"key":"167_CR7","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1053\/j.gastro.2008.05.047","volume":"135","author":"DC Metz","year":"2008","unstructured":"Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008;135:1469\u201392.","journal-title":"Gastroenterology."},{"key":"167_CR8","doi-asserted-by":"crossref","first-page":"427","DOI":"10.4318\/tjg.2012.0552","volume":"23","author":"BH Demirkan","year":"2012","unstructured":"Demirkan BH, Eriksson B. Systemic treatment of neuroendocrine tumors with hepatic metastases. Turk J Gastroenterol. 2012;23:427\u201337.","journal-title":"Turk J Gastroenterol"},{"key":"167_CR9","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.drudis.2013.10.015","volume":"19","author":"F Barbieri","year":"2014","unstructured":"Barbieri F, Albertelli M, Grillo F, Mohamed A, Saveanu A, Barlier A, et al. Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies. Drug Discov Today. 2014;19:458\u201368.","journal-title":"Drug Discov Today"},{"key":"167_CR10","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.clon.2011.12.003","volume":"24","author":"KY Gulenchyn","year":"2012","unstructured":"Gulenchyn KY, Yao X, Asa SL, Singh S, Law C. Radionuclide therapy in neuroendocrine tumours: a systematic review. Clin Oncol (R Coll Radiol). 2012;24:294\u2013308.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"167_CR11","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/annonc\/mdp334","volume":"21","author":"L Righi","year":"2010","unstructured":"Righi L, Volante M, Tavaglione V, Bille A, Daniele L, Angusti T, et al. Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 \u2018clinically aggressive\u2019 cases. Ann Oncol. 2010;21:548\u201355.","journal-title":"Ann Oncol."},{"key":"167_CR12","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","volume":"26","author":"DJ Kwekkeboom","year":"2008","unstructured":"Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP. et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124\u201330.","journal-title":"J Clin Oncol"},{"key":"167_CR13","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1097\/JTO.0b013e31828c2900","volume":"8","author":"JS Barbieri","year":"2013","unstructured":"Barbieri JS, Seshasai R, Shemesh A, Sedrak M, Hoffman B, Alley EW. Thymic neuroendocrine tumor presenting with the ectopic ACTH syndrome. J Thorac Oncol. 2013;8:e57\u20138.","journal-title":"J Thorac Oncol"},{"key":"167_CR14","doi-asserted-by":"crossref","first-page":"R453","DOI":"10.1530\/ERC-17-0531","volume":"25","author":"F Grillo","year":"2018","unstructured":"Grillo F, Florio T, Ferrau F, Kara E, Fanciulli G, Faggiano A, et al. Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms. Endocr Relat Cancer. 2018;25:R453\u201366.","journal-title":"Endocr Relat Cancer"},{"key":"167_CR15","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514\u201323.","journal-title":"N Engl J Med"},{"key":"167_CR16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1158\/0008-5472.CAN-11-2089","volume":"73","author":"SE Pool","year":"2013","unstructured":"Pool SE, Bison S, Koelewijn SJ, van der Graaf LM, Melis M, Krenning EP, et al. mTOR inhibitor RAD001 promotes metastasis in a rat model of pancreatic neuroendocrine cancer. Cancer Res. 2013;73:12\u20138.","journal-title":"Cancer Res."},{"key":"167_CR17","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1634\/theoncologist.2011-0031","volume":"16","author":"TA Mohammed","year":"2011","unstructured":"Mohammed TA, Holen KD, Jaskula-Sztul R, Mulkerin D, Lubner SJ, Schelman WR, et al. A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma. Oncologist. 2011;16:835\u201343.","journal-title":"Oncologist."},{"key":"167_CR18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1530\/ERC-15-0002","volume":"22","author":"A Dasari","year":"2015","unstructured":"Dasari A, Phan A, Gupta S, Rashid A, Yeung SC, Hess K, et al. Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors. Endocr Relat Cancer. 2015;22:431\u201341.","journal-title":"Endocr Relat Cancer"},{"key":"167_CR19","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S0002-9440(10)64645-7","volume":"157","author":"GM Portela-Gomes","year":"2000","unstructured":"Portela-Gomes GM, Lukinius A, Grimelius L. Synaptic vesicle protein 2, A new neuroendocrine cell marker. Am J Pathol. 2000;157:1299\u2013309.","journal-title":"Am J Pathol"},{"key":"167_CR20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/path.1002","volume":"196","author":"AM Jakobsen","year":"2002","unstructured":"Jakobsen AM, Ahlman H, Wangberg B, Kolby L, Bengtsson M, Nilsson O. Expression of synaptic vesicle protein 2 (SV2) in neuroendocrine tumours of the gastrointestinal tract and pancreas. J Pathol. 2002;196:44\u201350.","journal-title":"J Pathol."},{"key":"167_CR21","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1196\/annals.1294.032","volume":"1014","author":"O Nilsson","year":"2004","unstructured":"Nilsson O, Jakobsen AM, Kolby L, Bernhardt P, Forssell-Aronsson E, Ahlman H. Importance of vesicle proteins in the diagnosis and treatment of neuroendocrine tumors. Ann N Y Acad Sci. 2004;1014:280\u20133.","journal-title":"Ann N Y Acad Sci"},{"key":"167_CR22","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1523\/JNEUROSCI.4521-08.2009","volume":"29","author":"WP Chang","year":"2009","unstructured":"Chang WP, Sudhof TC. SV2 renders primed synaptic vesicles competent for Ca2\u2009+\u2009-induced exocytosis. J Neurosci. 2009;29:883\u201397.","journal-title":"J Neurosci."},{"key":"167_CR23","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0083-6729(08)00616-X","volume":"80","author":"JC Hou","year":"2009","unstructured":"Hou JC, Min L, Pessin JE. Insulin granule biogenesis, trafficking and exocytosis. Vitam Horm. 2009;80:473\u2013506.","journal-title":"Vitam Horm"},{"key":"167_CR24","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1021\/bi0356698","volume":"43","author":"JE Keller","year":"2004","unstructured":"Keller JE, Cai F, Neale EA. Uptake of botulinum neurotoxin into cultured neurons. Biochemistry. 2004;43:526\u201332.","journal-title":"Biochemistry."},{"key":"167_CR25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev-pharmtox-011613-135935","volume":"54","author":"G Masuyer","year":"2014","unstructured":"Masuyer G, Chaddock JA, Foster KA, Acharya KR. Engineered botulinum neurotoxins as new therapeutics. Annu Rev Pharmacol Toxicol. 2014;54:27\u201351.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"167_CR26","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev.biochem.051908.125345","volume":"79","author":"M Montal","year":"2010","unstructured":"Montal M. Botulinum neurotoxin: a marvel of protein design. Annu Rev Biochem. 2010;79:591\u2013617.","journal-title":"Annu Rev Biochem"},{"key":"167_CR27","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","volume":"132","author":"CH Moskowitz","year":"2018","unstructured":"Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132:2639\u201342.","journal-title":"Blood."},{"key":"167_CR28","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s10637-017-0473-9","volume":"35","author":"K Almhanna","year":"2017","unstructured":"Almhanna K, Wright D, Mercade TM, Van Laethem JL, Gracian AC, Guillen-Ponce C, et al. A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C. Invest New Drugs. 2017;35:634\u201341.","journal-title":"Invest New Drugs"},{"key":"167_CR29","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1200\/JCO.2013.54.8115","volume":"32","author":"PA Ott","year":"2014","unstructured":"Ott PA, Hamid O, Pavlick AC, Kluger H, Kim KB, Boasberg PD, et al. Phase I\/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma. J Clin Oncol. 2014;32:3659\u201366.","journal-title":"J Clin Oncol"},{"key":"167_CR30","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/jnc.12284","volume":"126","author":"J Arsenault","year":"2013","unstructured":"Arsenault J, Ferrari E, Niranjan D, Cuijpers SA, Gu C, Vallis Y, et al. Stapling of the botulinum type A protease to growth factors and neuropeptides allows selective targeting of neuroendocrine cells. J Neurochem. 2013;126:223\u201333.","journal-title":"J Neurochem."},{"key":"167_CR31","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bej.2017.05.007","volume":"124","author":"N Xu","year":"2017","unstructured":"Xu N, Ma C, Ou J, Sun WW, Zhou L, Hu H, et al. Comparative Proteomic Analysis of Three Chinese Hamster Ovary (CHO) Host Cells. Biochem Eng J. 2017;124:122\u20139.","journal-title":"Biochem Eng J"},{"key":"167_CR32","doi-asserted-by":"crossref","unstructured":"Xu N, Ou J, Gilani A-K, Zhou L, Liu M. High-level expression of recombinant IgG1 by CHO K1 platform. Frontiers of Chemical Science and Engineering. 2015;9:376\u201380.","DOI":"10.1007\/s11705-015-1531-5"},{"key":"167_CR33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1124\/pr.114.009373","volume":"68","author":"P Polakis","year":"2016","unstructured":"Polakis P. Antibody drug conjugates for cancer therapy. Pharmacol Rev. 2016;68:3\u201319.","journal-title":"Pharmacol Rev."},{"key":"167_CR34","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.amjsurg.2010.08.018","volume":"201","author":"B Zarebczan","year":"2011","unstructured":"Zarebczan B, Pinchot SN, Kunnimalaiyaan M, Chen H. Hesperetin, a potential therapy for carcinoid cancer. Am J Surg. 2011;201:329\u201332.","journal-title":"Am J Surg"},{"key":"167_CR35","first-page":"492","volume":"58","author":"A Khan","year":"2012","unstructured":"Khan A, Gillis K, Clor J, Tyagarajan K. Simplified evaluation of apoptosis using the Muse cell analyzer. Postepy Biochem. 2012;58:492\u20136.","journal-title":"Postepy Biochem."},{"key":"167_CR36","volume-title":"Practical Nonparametric Statistics.","author":"WJ Conover","year":"1999","unstructured":"Conover WJ. Practical Nonparametric Statistics. 3rd ed. Hoboken, NJ: Wiley; 1999.","edition":"3rd ed."},{"key":"167_CR37","first-page":"122","volume-title":"Understanding heart sounds and murmurs.","author":"AG Tilkian","year":"1979","unstructured":"Tilkian AG, Conover MB. Understanding heart sounds and murmurs. xii. Philadelphia: Saunders; 1979. p. 122."},{"key":"167_CR38","first-page":"65","volume":"6","author":"S Holm","year":"1979","unstructured":"Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6:65\u201370.","journal-title":"Scand J Stat"},{"key":"167_CR39","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1123654","volume":"312","author":"M Dong","year":"2006","unstructured":"Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, et al. SV2 is the protein receptor for botulinum neurotoxin A. Science. 2006;312:592\u20136.","journal-title":"Science"},{"key":"167_CR40","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/toxsci\/kft082","volume":"134","author":"WS Hong","year":"2013","unstructured":"Hong WS, Young EW, Tepp WH, Johnson EA, Beebe DJ. A microscale neuron and Schwann cell coculture model for increasing detection sensitivity of botulinum neurotoxin type A. Toxicol Sci. 2013;134:64\u201372.","journal-title":"Toxicol Sci"},{"key":"167_CR41","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1200\/JCO.2005.05.4106","volume":"24","author":"RG Martins","year":"2006","unstructured":"Martins RG, Rajendran JG, Capell P, Byrd DR, Mankoff DA. Medullary thyroid cancer: options for systemic therapy of metastatic disease? J Clin Oncol. 2006;24:1653\u20135.","journal-title":"J Clin Oncol"},{"key":"167_CR42","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.apmr.2009.03.008","volume":"90","author":"CL Chang","year":"2009","unstructured":"Chang CL, Munin MC, Skidmore ER, Niyonkuru C, Huber LM, Weber DJ. Effect of baseline spastic hemiparesis on recovery of upper-limb function following botulinum toxin type A injections and postinjection therapy. Arch Phys Med Rehabil. 2009;90:1462\u20138.","journal-title":"Arch Phys Med Rehabil"},{"key":"167_CR43","doi-asserted-by":"crossref","first-page":"C960","DOI":"10.1152\/ajpcell.00259.2010","volume":"299","author":"A Nowack","year":"2010","unstructured":"Nowack A, Yao J, Custer KL, Bajjalieh SM. SV2 regulates neurotransmitter release via multiple mechanisms. Am J Physiol Cell Physiol. 2010;299:C960\u20137.","journal-title":"Am J Physiol Cell Physiol"},{"key":"167_CR44","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/1087057115608103","volume":"21","author":"WS Hong","year":"2016","unstructured":"Hong WS, Pezzi HM, Schuster AR, Berry SM, Sung KE, Beebe DJ. Development of a highly sensitive cell-based assay for detecting botulinum neurotoxin type A through neural culture media optimization. J Biomol Screen. 2016;21:65\u201373.","journal-title":"J Biomol Screen"},{"key":"167_CR45","doi-asserted-by":"crossref","unstructured":"Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132:2639\u201342.","DOI":"10.1182\/blood-2018-07-861641"},{"key":"167_CR46","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1200\/JCO.2013.52.5683","volume":"32","author":"J Bendell","year":"2014","unstructured":"Bendell J, Saleh M, Rose AA, Siegel PM, Hart L, Sirpal S, et al. Phase I\/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer. J Clin Oncol. 2014;32:3619\u201325.","journal-title":"J Clin Oncol"},{"key":"167_CR47","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1111\/j.1471-4159.1971.tb03750.x","volume":"18","author":"LL Simpson","year":"1971","unstructured":"Simpson LL, Rapport MM. The binding of botulinum toxin to membrane lipids: sphingolipids, steroids and fatty acids. J Neurochem. 1971;18:1751\u20139.","journal-title":"J Neurochem."},{"key":"167_CR48","doi-asserted-by":"crossref","first-page":"32815","DOI":"10.1074\/jbc.M205258200","volume":"277","author":"BC Yowler","year":"2002","unstructured":"Yowler BC, Kensinger RD, Schengrund CL. Botulinum neurotoxin A activity is dependent upon the presence of specific gangliosides in neuroblastoma cells expressing synaptotagmin I. J Biol Chem. 2002;277:32815\u20139.","journal-title":"J Biol Chem"},{"key":"167_CR49","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1091\/mbc.e08-07-0765","volume":"19","author":"M Dong","year":"2008","unstructured":"Dong M, Liu H, Tepp WH, Johnson EA, Janz R, Chapman ER. Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol Biol Cell. 2008;19:5226\u201337.","journal-title":"Mol Biol Cell"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41417-020-0167-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41417-020-0167-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41417-020-0167-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:10:52Z","timestamp":1684617052000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-020-0167-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,7]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["167"],"URL":"https:\/\/doi.org\/10.1038\/s41417-020-0167-x","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,7]]},"assertion":[{"value":"14 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}